← All trials
NCT05183178
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2022
- Primary completion
- Jan 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Jan 10, 2022
- Last posted
- Mar 17, 2022
- Enrollment
- 16000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vastra Gotaland RegionLead sponsor
- Region SkaneCollaborator
- Uppsala UniversityCollaborator
- Orebro UniversityCollaborator
- University of GothenburgOverall official - principal investigator
- Government of SwedenCollaborator
- Västerbotten County CouncilCollaborator
- Region HallandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.